Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma

Mian M.K. Shahzad; Yong Hyun Shin; Koji Matsuo; Chunhua Lu; Masato Nishimura; De Yo Shen; Yu Kang; Wei Hu; Edna M. Mora; Cristian Rodriguez-Aguayo; Arvinder Kapur; Justin Bottsford-Miller; Gabriel Lopez-Berestein; Aleksandar Rajkovic; Anil K. Sood

doi:10.1016/j.canlet.2012.07.001

Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma

Mian M.K. Shahzad, Yong Hyun Shin, Koji Matsuo, Chunhua Lu, Masato Nishimura, De Yo Shen, Yu Kang, Wei Hu, Edna M. Mora, Cristian Rodriguez-Aguayo, Arvinder Kapur, Justin Bottsford-Miller, Gabriel Lopez-Berestein, Aleksandar Rajkovic, Anil K. Sood

Research output: Contribution to journal › Review article › peer-review

25 Scopus citations

Abstract

The present study was undertaken to determine the expression and biological significance of HORMAD1 in human epithelial ovarian carcinoma. We found that a substantial proportion of human epithelial ovarian cancers expressed HORMAD1. In vitro, HORMAD1 siRNA enhanced docetaxel induced apoptosis and substantially reduced the invasive and migratory potential of ovarian cancer cells (2774). In vivo, HORMAD1 siRNA-DOPC treatment resulted in reduced tumor weight, which was further enhanced in combination with cisplatin. HORMAD1 gene silencing resulted in significantly reduced VEGF protein levels and microvessel density compared to controls. Our data suggest that HORMAD1 may be an important therapeutic target.

Original language	English (US)
Pages (from-to)	123-129
Number of pages	7
Journal	Cancer Letters
Volume	330
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2012.07.001
State	Published - Apr 28 2013

Keywords

Angiogenesis
HORMAD1
Ovarian cancer
VEGF
Xenograft

ASJC Scopus subject areas

Oncology
Cancer Research

MD Anderson CCSG core facilities

Advanced Technology Genomics Core
Tissue Biospecimen and Pathology Resource
Cytogenetics and Cell Authentication Core
Clinical Trials Office

Access to Document

10.1016/j.canlet.2012.07.001

Cite this

Shahzad, M. M. K., Shin, Y. H., Matsuo, K., Lu, C., Nishimura, M., Shen, D. Y., Kang, Y., Hu, W., Mora, E. M., Rodriguez-Aguayo, C., Kapur, A., Bottsford-Miller, J., Lopez-Berestein, G., Rajkovic, A., & Sood, A. K. (2013). Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Letters, 330(2), 123-129. https://doi.org/10.1016/j.canlet.2012.07.001

Shahzad, MMK, Shin, YH, Matsuo, K, Lu, C, Nishimura, M, Shen, DY, Kang, Y, Hu, W, Mora, EM, Rodriguez-Aguayo, C, Kapur, A, Bottsford-Miller, J, Lopez-Berestein, G, Rajkovic, A & Sood, AK 2013, 'Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma', Cancer Letters, vol. 330, no. 2, pp. 123-129. https://doi.org/10.1016/j.canlet.2012.07.001

@article{98eecec3f8e648b0b81e59126136b14c,

title = "Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma",

abstract = "The present study was undertaken to determine the expression and biological significance of HORMAD1 in human epithelial ovarian carcinoma. We found that a substantial proportion of human epithelial ovarian cancers expressed HORMAD1. In vitro, HORMAD1 siRNA enhanced docetaxel induced apoptosis and substantially reduced the invasive and migratory potential of ovarian cancer cells (2774). In vivo, HORMAD1 siRNA-DOPC treatment resulted in reduced tumor weight, which was further enhanced in combination with cisplatin. HORMAD1 gene silencing resulted in significantly reduced VEGF protein levels and microvessel density compared to controls. Our data suggest that HORMAD1 may be an important therapeutic target.",

keywords = "Angiogenesis, HORMAD1, Ovarian cancer, VEGF, Xenograft",

author = "Shahzad, {Mian M.K.} and Shin, {Yong Hyun} and Koji Matsuo and Chunhua Lu and Masato Nishimura and Shen, {De Yo} and Yu Kang and Wei Hu and Mora, {Edna M.} and Cristian Rodriguez-Aguayo and Arvinder Kapur and Justin Bottsford-Miller and Gabriel Lopez-Berestein and Aleksandar Rajkovic and Sood, {Anil K.}",

note = "Funding Information: M.M.S. is supported by the GCF-Molly Cade ovarian cancer research grant and the NIH/NICHD Baylor WRHR Scholarship Grant (HD050128). This research was funded in part by a Program Project Development Grant from the Ovarian Cancer Research Fund, Inc., the Zarrow Foundation, NIH Grants (CA 110793, 109298, P50 CA083639, P50 CA098258, CA128797, CA 009614, RC2GM092599, U54 CA151668), The Marcus Foundation, and the Betty Ann Asche Murray Distinguished Professorship, NIH/NCHD Grant (HD054829) and Duncan pilot project. National Institutes of Health Grant HD054829 and March of Dimes Grant (#6-FY08-313) to AR. ",

year = "2013",

month = apr,

day = "28",

doi = "10.1016/j.canlet.2012.07.001",

language = "English (US)",

volume = "330",

pages = "123--129",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma

AU - Shahzad, Mian M.K.

AU - Shin, Yong Hyun

AU - Matsuo, Koji

AU - Lu, Chunhua

AU - Nishimura, Masato

AU - Shen, De Yo

AU - Kang, Yu

AU - Hu, Wei

AU - Mora, Edna M.

AU - Rodriguez-Aguayo, Cristian

AU - Kapur, Arvinder

AU - Bottsford-Miller, Justin

AU - Lopez-Berestein, Gabriel

AU - Rajkovic, Aleksandar

AU - Sood, Anil K.

N1 - Funding Information: M.M.S. is supported by the GCF-Molly Cade ovarian cancer research grant and the NIH/NICHD Baylor WRHR Scholarship Grant (HD050128). This research was funded in part by a Program Project Development Grant from the Ovarian Cancer Research Fund, Inc., the Zarrow Foundation, NIH Grants (CA 110793, 109298, P50 CA083639, P50 CA098258, CA128797, CA 009614, RC2GM092599, U54 CA151668), The Marcus Foundation, and the Betty Ann Asche Murray Distinguished Professorship, NIH/NCHD Grant (HD054829) and Duncan pilot project. National Institutes of Health Grant HD054829 and March of Dimes Grant (#6-FY08-313) to AR.

PY - 2013/4/28

Y1 - 2013/4/28

N2 - The present study was undertaken to determine the expression and biological significance of HORMAD1 in human epithelial ovarian carcinoma. We found that a substantial proportion of human epithelial ovarian cancers expressed HORMAD1. In vitro, HORMAD1 siRNA enhanced docetaxel induced apoptosis and substantially reduced the invasive and migratory potential of ovarian cancer cells (2774). In vivo, HORMAD1 siRNA-DOPC treatment resulted in reduced tumor weight, which was further enhanced in combination with cisplatin. HORMAD1 gene silencing resulted in significantly reduced VEGF protein levels and microvessel density compared to controls. Our data suggest that HORMAD1 may be an important therapeutic target.

AB - The present study was undertaken to determine the expression and biological significance of HORMAD1 in human epithelial ovarian carcinoma. We found that a substantial proportion of human epithelial ovarian cancers expressed HORMAD1. In vitro, HORMAD1 siRNA enhanced docetaxel induced apoptosis and substantially reduced the invasive and migratory potential of ovarian cancer cells (2774). In vivo, HORMAD1 siRNA-DOPC treatment resulted in reduced tumor weight, which was further enhanced in combination with cisplatin. HORMAD1 gene silencing resulted in significantly reduced VEGF protein levels and microvessel density compared to controls. Our data suggest that HORMAD1 may be an important therapeutic target.

KW - Angiogenesis

KW - HORMAD1

KW - Ovarian cancer

KW - VEGF

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=84873080618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873080618&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.07.001

DO - 10.1016/j.canlet.2012.07.001

M3 - Review article

C2 - 22776561

AN - SCOPUS:84873080618

SN - 0304-3835

VL - 330

SP - 123

EP - 129

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this